Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (22)

2024

  1. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  2. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

  3. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population

    The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202

  2. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  2. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain

    Frontiers in Endocrinology, Vol. 13

2021

  1. Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain

    Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936

  2. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey

    Pituitary, Vol. 23, Núm. 2, pp. 129-139

  2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

2019

  1. Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly

    EBioMedicine, Vol. 43, pp. 537-552

2018

  1. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305

2016

  1. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY

    Pituitary, Vol. 19, Núm. 2, pp. 127-137

2013

  1. Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

    Pituitary, Vol. 16, Núm. 1, pp. 115-121

  2. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues

    European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13

  3. Pegvisomant and cabergoline combination therapy in acromegaly

    Pituitary, Vol. 16, Núm. 1, pp. 101-108

2011

  1. Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type

    BMC Medical Genetics, Vol. 12

  2. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

    Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2

2010

  1. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154